Rigel Pharma (RIGL) Forecasted to double in stock price!

STA Research
by: STA Research

Rigel Pharmaceuticals Inc is a clinical-stage drug development company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.

Our STA Research today shows that the stock is due for a 96% increase in it’s stock valuation within a 6 to 12 month duration.  Yahoo Finance Analyst Report indicates a 96%  increase. Our STA Research rating indicates the stock as a Very Strong Buy with Bearish near term sentiment.


Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.